Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)”

108 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 108 results

Early research (Phase 1)Ended earlyNCT03739138
What this trial is testing

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Who this might be right for
Advanced Solid Tumors
Merck Sharp & Dohme LLC 30
Testing effectiveness (Phase 2)Study completedNCT02853344
What this trial is testing

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 275
Testing effectiveness (Phase 2)Active Not RecruitingNCT06041802
What this trial is testing

Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Who this might be right for
Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 19
Large-scale testing (Phase 3)Study completedNCT03833167
What this trial is testing

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Who this might be right for
Carcinoma, Squamous Cell
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 140
Large-scale testing (Phase 3)Study completedNCT03517449
What this trial is testing

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Who this might be right for
Endometrial Neoplasms
Eisai Inc. 827
Large-scale testing (Phase 3)Active Not RecruitingNCT03765918
What this trial is testing

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Who this might be right for
Head and Neck Neoplasms
Merck Sharp & Dohme LLC 714
Large-scale testing (Phase 3)Study completedNCT03713593
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 794
Large-scale testing (Phase 3)Study completedNCT04889118
What this trial is testing

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Who this might be right for
Malignant Melanoma
Merck Sharp & Dohme LLC 131
Large-scale testing (Phase 3)Study completedNCT03783078
What this trial is testing

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Who this might be right for
Merkel Cell Carcinoma
Merck Sharp & Dohme LLC 55
Large-scale testing (Phase 3)Active Not RecruitingNCT04634877
What this trial is testing

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Who this might be right for
Endometrial Neoplasms
Merck Sharp & Dohme LLC 990
Early research (Phase 1)Study completedNCT04153565
What this trial is testing

Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Who this might be right for
Mesothelioma
Merck Sharp & Dohme LLC 19
Large-scale testing (Phase 3)Looking for participantsNCT06623422
What this trial is testing

Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 680
Large-scale testing (Phase 3)Study completedNCT04716933
What this trial is testing

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Who this might be right for
Nonsquamous Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 201
Early research (Phase 1)Active Not RecruitingNCT06049212
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Who this might be right for
Non-small Cell Lung CancerSolid TumorsProgrammed Cell Death-1 (PD1, PD-1)+2 more
Merck Sharp & Dohme LLC 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05609968
What this trial is testing

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 614
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Active Not RecruitingNCT06307431
What this trial is testing

Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 272
Large-scale testing (Phase 3)Active Not RecruitingNCT04956692
What this trial is testing

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 531
Next Page